AU2020332268B2 - Novel peptide, compositions and method for delivery of agents into cells and tissues - Google Patents

Novel peptide, compositions and method for delivery of agents into cells and tissues Download PDF

Info

Publication number
AU2020332268B2
AU2020332268B2 AU2020332268A AU2020332268A AU2020332268B2 AU 2020332268 B2 AU2020332268 B2 AU 2020332268B2 AU 2020332268 A AU2020332268 A AU 2020332268A AU 2020332268 A AU2020332268 A AU 2020332268A AU 2020332268 B2 AU2020332268 B2 AU 2020332268B2
Authority
AU
Australia
Prior art keywords
peptide
nucl
cell
onl
decorin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2020332268A
Other languages
English (en)
Other versions
AU2020332268A1 (en
Inventor
Rajendra Kumar-Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of AU2020332268A1 publication Critical patent/AU2020332268A1/en
Application granted granted Critical
Publication of AU2020332268B2 publication Critical patent/AU2020332268B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020332268A 2019-07-02 2020-07-02 Novel peptide, compositions and method for delivery of agents into cells and tissues Expired - Fee Related AU2020332268B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962869831P 2019-07-02 2019-07-02
US62/869,831 2019-07-02
PCT/US2020/040720 WO2021034418A2 (en) 2019-07-02 2020-07-02 Novel peptide, compositions and method for delivery of agents into cells and tissues

Publications (2)

Publication Number Publication Date
AU2020332268A1 AU2020332268A1 (en) 2022-02-24
AU2020332268B2 true AU2020332268B2 (en) 2025-04-24

Family

ID=74659924

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020332268A Expired - Fee Related AU2020332268B2 (en) 2019-07-02 2020-07-02 Novel peptide, compositions and method for delivery of agents into cells and tissues

Country Status (9)

Country Link
US (2) US11713337B2 (https=)
EP (1) EP3994151A4 (https=)
JP (1) JP7581264B2 (https=)
KR (1) KR20220039725A (https=)
CN (1) CN114555625B (https=)
AU (1) AU2020332268B2 (https=)
CA (1) CA3144963A1 (https=)
IL (1) IL289516A (https=)
WO (1) WO2021034418A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3100276A1 (en) 2018-06-06 2019-12-12 Massachusetts Institute Of Technology Circular rna for translation in eukaryotic cells
WO2026005189A1 (ko) * 2024-06-27 2026-01-02 이엔셀 주식회사 안구 세포 또는 조직을 표적하는 펩타이드 및 이를 포함하는 바이러스 캡시드 단백질 및 바이러스 벡터

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625155A1 (en) * 2003-05-19 2006-02-15 Dermagen AB Novel antimicrobial peptides with heparin binding activity
WO2009033731A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a laminin peptide as a therapeutic agent
US20170349628A1 (en) * 2014-10-02 2017-12-07 Temple University-Of The Commonwealth System Of Higher Education Synthesis of Cell Penetrating Peptides for Drug Delivery and Stem Cell Applications
US20180055958A1 (en) * 2015-03-12 2018-03-01 Sanyo Chemical Industries, Ltd. Method for producing protein composition, and protein composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211657A (en) * 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
JP3635462B2 (ja) * 2000-05-31 2005-04-06 国立医薬品食品衛生研究所長 アデノウイルスベクター
US8076295B2 (en) * 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
AU2008295509A1 (en) * 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
CN102869384B (zh) * 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
US20130158103A1 (en) * 2011-11-23 2013-06-20 The Curators Of The University Of Missouri Method of Tissue-Selective Targeted Gene Transfer
EP3076792B1 (en) * 2013-12-04 2020-11-11 Newleaf Symbiotics, Inc. Compositions and methods for improving lettuce production
US9738687B2 (en) * 2015-04-10 2017-08-22 Feldan Bio Inc. Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625155A1 (en) * 2003-05-19 2006-02-15 Dermagen AB Novel antimicrobial peptides with heparin binding activity
WO2009033731A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a laminin peptide as a therapeutic agent
US20170349628A1 (en) * 2014-10-02 2017-12-07 Temple University-Of The Commonwealth System Of Higher Education Synthesis of Cell Penetrating Peptides for Drug Delivery and Stem Cell Applications
US20180055958A1 (en) * 2015-03-12 2018-03-01 Sanyo Chemical Industries, Ltd. Method for producing protein composition, and protein composition

Also Published As

Publication number Publication date
US20230340024A1 (en) 2023-10-26
AU2020332268A1 (en) 2022-02-24
KR20220039725A (ko) 2022-03-29
CN114555625A (zh) 2022-05-27
WO2021034418A2 (en) 2021-02-25
JP7581264B2 (ja) 2024-11-12
CN114555625B (zh) 2025-02-25
JP2022538903A (ja) 2022-09-06
WO2021034418A3 (en) 2021-04-01
US11713337B2 (en) 2023-08-01
EP3994151A2 (en) 2022-05-11
IL289516A (en) 2022-03-01
EP3994151A4 (en) 2023-07-19
US20220204562A1 (en) 2022-06-30
CA3144963A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
AU2019360372B2 (en) Intein proteins and uses thereof
Liu et al. Penetratin, a potentially powerful absorption enhancer for noninvasive intraocular drug delivery
CA2901439C (en) Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
Johnson et al. Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin
US20230340024A1 (en) Novel peptide, compositions and method for delivery of agents into cells and tissues
JP2018531624A (ja) 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療
Zhang et al. Tat PTD–endostatin: A novel anti-angiogenesis protein with ocular barrier permeability via eye-drops
JP2012519696A (ja) 光受容細胞のアポトーシスを抑制する方法
Liu et al. siRNA silencing of gene expression in trabecular meshwork: RhoA siRNA reduces IOP in mice
Kumar et al. Cell-Penetrating chaperone Nuc1 for Small-and Large-Molecule delivery into retinal cells and tissues
US20160144055A1 (en) Gene therapy vector for treatment of steroid glaucoma
US20190142915A1 (en) Ocular delivery of cell permeant therapeutics for the treatment of retinal edema
Wu et al. Tropism and retinal transduction efficiency of adeno-associated virus serotypes in mice
EA048046B1 (ru) Новый пептид, композиции и способ доставки агентов в клетки и ткани
Hao et al. Co-overexpression of Atoh1, Pou4f3, and Gfi1 enhances the transdifferentiation of supporting cells into hair cells in the neonatal mouse utricle
US20230135501A1 (en) Gene therapy
Zhang et al. A potential therapeutic strategy for inhibition of ocular neovascularization with a new endogenous protein: rhEDI-8t
US20230190869A1 (en) Peptide inhibitors of guanine nucleotide exchange factor h-1
US20250177573A1 (en) Materials & Methods for Treatment of Macular Degeneration
US20230416315A1 (en) Prion-fc region fusion protein and use thereof
Read Non-Viral Gene Therapy for the Treatment of Retinal Degeneration
JP2020517714A (ja) 処置方法および新規構築物

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application